Knoll Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 18-07-2024
- Paid Up Capital ₹ 1.36 M
as on 18-07-2024
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue -59.56%
(FY 2023)
- Profit -75.39%
(FY 2023)
- Ebitda -69.80%
(FY 2023)
- Net Worth 2.48%
(FY 2023)
- Total Assets -47.95%
(FY 2023)
About Knoll Pharmaceuticals
The Corporate was formerly known as J.B.B. Healthcare Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.36 M, as per Ministry of Corporate Affairs (MCA) records.
Vikas Goel, Sunil Goel, and Vishnu Goel serve as directors at the Company.
- CIN/LLPIN
U00304DL2005PLC140896
- Company No.
140896
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Sep 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Badli, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Knoll Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Goel  | Director | 19-Sep-2005 | Current |
| Sunil Goel | Director | 01-Nov-2011 | Current |
| Vishnu Goel | Director | 19-Sep-2005 | Current |
Financial Performance and Corporate Structure Insights of Knoll Pharmaceuticals.
Knoll Pharmaceuticals Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59.56% decrease. The company also saw a substantial fall in profitability, with a 75.39% decrease in profit. The company's net worth moved up by a moderate rise of 2.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Knoll Pharmaceuticals?
In 2023, Knoll Pharmaceuticals had a promoter holding of 45.29% and a public holding of 54.71%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bioford Remedies Private Limited
Active 13 years 11 monthsVikas Goel and Sunil Goel are mutual person
Knoll Healthcare Private Limited
Active 16 years 6 monthsVikas Goel and Sunil Goel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Knoll Pharmaceuticals?
Knoll Pharmaceuticals has a workforce of 2 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Knoll Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Knoll Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
